Sodium-Glucose相关论文
Fulminant type 1 diabetes mellitus(FT1DM)is a subtype of type 1 diabetes mellitus characterized by an abrupt onset and a......
Polycystic ovary syndrome(PCOS)is the most common endocrinopathy in women of reproductive age associated with long-term ......
BACKGROUND Modern guidelines recommend sodium-glucose cotransporter-2(SGLT2)inhibitors as the preferred antihyperglycemi......
Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver dis
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent cause of chronic liver disease worldwide. NAFLD is consid......
Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomi
Objective To assess the efficiency and safety of a novel sodium-glucose co-transporter 2 (SGLT2)inhibitor-SGLT2 inhibito......
Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: C
Cardiovascular diseases (CVDs) remain the leading cause of death in the world and in most developed countries. Patients ......
Mechanism Underlying Increase of the Serum Magnesium Concentration Observed Following Treatment with
Aim: The EMPA-REG OUTCOME study reported that the sodium-glucose cotransporter 2 inhibitor (SGLT2-i) suppressed cardiova......
Discovery of Novel N-Glycoside and Non-Glycoside hSGLT2 Inhibitors for the Treatment of Type 2 Diabe
Human sodium-glucose cotransporter 2 (hSGLT2) is a membrane protein responsible for glucose reabsorption from the glomer......
Sodium-glucose cotransporter 2 （SGLT2） inhibitioninduces glucosuria and decreases blood glucose levelsin diabetic patients......
Three major cardiovascular outcome trials(CVOTs)with a new class of antidiabetic drugs-sodium-glucose cotransporter 2(SG......
Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients wi
Heart failure(HF)is a major complication of diabetes mellitus(DM).Patients with DM have considerably higher risk for HF ......
AIM To evaluate the effect on cardiovascular outcomes of sodium-glucose co-transporter-2(SGLT2)inhibitors in a real worl......
Canagliflozin(CFZ) is a member of new class of glucose lowering agents, sodium-glucose co-transporter(SGLT) inhibitors, ......
